

## FACULTY

G. Abbruzzese (Genova)	F. Marrosu (Cagliari)
V. Agnetti (Sassari)	W. Meissner (Bordeaux, France)
M. Amboni (Napoli)	M. Melis (Cagliari)
A. Antonini (Venezia)	A. Milia (Cagliari)
J.P. Azulay (Marseille, France)	N. Modugno (Pozzilli, IS)
P. Barone (Salerno)	M. Morelli (Cagliari)
A. Berardelli (Roma)	F. Morgante (Messina)
V. Bonifati (Rotterdam)	D. Murgia (Cagliari)
U. Bonuccelli (Pisa)	K. Paulus (Sassari)
A. Cannas (Cagliari)	M. Pilleri (Venezia)
A.R. Carta (Cagliari)	W. Poewe (Innsbruck, Austria)
M. Carta (Cagliari-Lund /Sweden)	O. Rascol (Toulouse, France)
R. Ceravolo (Pisa)	V. Ricchi (Cagliari)
R. Cilia (Milano)	G. Rizzo (Bologna)
C. Colosimo (Roma)	U. Sabbatini (Roma)
G. Cossu (Cagliari)	V. Saggi (Nuoro)
G. De Fazio (Bari)	G. Serra (Cagliari)
G. Di Chiara (Cagliari)	P. Solla (Monserrato)
G. Fabbrini (Roma)	F. Stocchi (Roma)
A. Fasano (Roma)	A. Tessitore (Napoli)
J.J. Ferreira (Lisbon, Portugal)	E. Tolosa (Barcelona, Spain)
A. Lees (London, UK)	S. Traccis (Sassari)
L. Lopiano (Torino)	M. Zibetti (Torino)

## GENERAL INFORMATION

### CONGRESS VENUE

Ex Seminario Pontificio Regionale  
Via Vittorio Emanuele, 78 • Cuglieri

### SCIENTIFIC INFORMATION

#### C.M.E. - Continuing Medical Education

The Congress is accredited by  
Aristea Education Official Provider  
(nr. 500 – 60930) for Continuing Medical  
Education (CME) to provide CME activity  
for medical specialists.

Full congress days count **9,8** credits.  
In order to obtain CME credits the  
Provider requires feedback on its  
educational activities. Therefore, we  
kindly ask delegates to complete the  
congress evaluation form included  
in the congress bag and return it to the  
registration desk on the last day of  
attendance. The certificate with the CME  
credits for the Congress will be available  
on line on the website  
<http://ecm.aristeaonline.it> after 60 days of  
the end of the congress.

### ORGANIZING SECRETARIAT



Via Lima, 31 • 00198 Roma  
Tel. 06 845431 • Fax 06 84543700  
[roma@aristea.com](mailto:roma@aristea.com) • [www.aristea.com](http://www.aristea.com)

The congress has been supported by  
unrestricted educational grant from:

abbvie



Medtronic



LIMPE  
LEGA ITALIANA PER LA LOTTA CONTRO  
LA MALATTIA DI PARKINSON  
LE SINDROMI EXTRAPIRAMIDALI E LE DEMENTIE



# OPEN ISSUES IN PARKINSON'S DISEASE: Questions and Answers

Cuglieri (OR)  
May 30-31, 2013

Ex Seminario  
Pontificio Regionale  
Via Vittorio Emanuele 78



## PROGRAM

### Thursday, May 30

#### 13.00 Welcome and introduction

*G. Cossu, N. Modugno, O. Rascol*

#### CLINICAL ISSUES IN PARKINSON'S DISEASE

CHAIRMEN: *A. Berardelli, O. Rascol*

#### 13.15 Toward a redefinition of Parkinson's disease

What is pre symptomatic in PD? Why is it important to detect early markers? How can we use them?  
*W. Poewe*

#### Discussion

What should we do to study early markers?  
*A. Tessitore*

#### 14.00 Tremor in PD

Are there different tremors in PD? What do they mean in terms of pathogenesis and prognosis? Does "Benign" tremulous PD exist? Are there specific medical and surgical treatments of PD tremor?  
*A. Lees*

#### Discussion

Anything else to better study parkinsonian tremors?  
*F. Morgante*

#### 15.00 Late-stage Parkinson disease

How is changing the landscape of PD's later stage? Beyond advanced phase of PD. Update focusing on dementia and gait/balance problems in the late stage of PD  
*J.J. Ferreira*

#### Discussion

Is there anything else we can do to study and manage cognition and gait/balance symptoms in the late phase?  
*A. Fasano*

#### 15.45 Non motor symptoms in PD, a general overview

How common are non motor symptoms (excluding gait and cognition) in PD? How do we detect them? How troublesome are they for the patients?  
*G. De Fazio*

#### Discussion

Future directions to better study non motor symptoms in PD  
*M. Amboni*

#### 16.30 Coffee Break

CHAIRMEN: *V. Agnetti, L. Lopiano, A. Milia*

#### 17.00 Focus on mood disorders in PD

Definition, prevalence, clinical importance, management  
*P. Barone*

#### Discussion

What else should be done to study mood disorders in PD?  
*C. Colosimo*

#### 17.45 Focus on apathy and impulsive control disorders in PD

Definition, prevalence, pathophysiology  
*J.P. Azulay*

#### Discussion

Future developments for understanding apathy and impulsive control disorders in  
*R. Cilia*

#### 18.30 Imaging

Update on neuroimaging in PD  
*U. Sabbatini*

#### Discussion

Is there anything else we can study with neuroimaging?  
*G. Rizzo*

#### CLOSING LECTURE

CHAIRMEN: *G. Abbruzzese, P. Barone*

#### 19.15 Future therapies for PD. Is there a role for pharmacogenetics?

*O. Rascol*

### Friday, May 31<sup>st</sup>

#### PATHOGENESIS AND EXPERIMENTAL THERAPEUTICS OF PARKINSON'S DISEASE

CHAIRMEN: *G. Abbruzzese, G. Di Chiara, M. Melis*

#### 08.30 Genetics in PD

Can the discovery of new mutations help us understanding the pathogenesis of PD and discovering the cure of PD?  
*V. Bonifati*

#### 09.00 Neuroinflammation in PD pathogenesis and therapy

How do neuroinflammatory mechanisms contribute to the cascade of events leading to neuronal degeneration? Do these events provide promising targets for future "neuroprotective" therapies of PD?  
*A.R. Carta*

#### 09.30 Dopamine-adenosine co-transmission as a therapeutic target in PD

How do adenosine contribute to the cascade of events leading to dopamine depletion? The A2A blockade still provide a promising targets for future "neuroprotective" therapies of PD?  
*M. Morelli*

#### 10.00 Alpha-synuclein in PD

Alpha synuclein as a relevant target for the treatment of PD?  
*W. Meissner*

#### 10.30 Coffee Break

#### TREATMENT OF PD

CHAIRMEN: *P. Barone, U. Bonuccelli, F. Marrosu*

#### 11.00 Oral Levodopa in 2013? Changing views and future perspectives

*E. Tolosa*

#### 11.30 Dopamine agonists in 2013? Old versus new DA agonists? What about the place of the DA agonists beyond 2013?

*R. Ceravolo*

#### 12.00 MAO-B and COMT- inhibitors: their place in 2013 and beyond?

*F. Stocchi*

#### 12.30 Discussion

#### 12.45 Lunch with VIDEOFORUM: Instructive cases of rare disease, uncommon aspects of parkinsonism

PANEL OF EXPERTS:

*V. Agnetti, A. Lees, W. Poewe, E. Tolosa*

Sardinian clinical cases presented by:

- *Daniela Murgia/Valeria Ricchi*
- *Paolo Solla*
- *Giulia Serra/Valeria Saggi*
- *Kai Paulus*
- *Manuela Pilleri*

#### TREATMENT OF PD

CHAIRMEN: *A. Cannas, G. Fabbrini, S. Tracis*

#### 14.00 Infusional therapies (apomorphine and levodopa): their place in 2013 and beyond?

*A. Antonini*

#### 14.30 Surgery (DBS and lesions) in 2013 and beyond? STN vs GPi, vs PPN, unilateral? Are still the STN or the GPi the principal targets? DBS: How to choose the best strategy

*M. Zibetti*

#### 15.00 Biotherapies in PD

The serotonergic system for the treatment of L-DOPA-induced dyskinesia: from animal models to clinical investigation  
*M. Carta*

#### 15.30 Discussion

#### 15.45 Final remarks and highlights

*G. Cossu, N. Modugno, O. Rascol*



**Cuglieri (OR)**  
May 30-31, 2013